Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 243410
For the Commercialization Licenses, Licensor grants to Licensee
– an exclusive right and license in the Territory, with the right to grant sublicenses, under Licensors rights in Licensor Intellectual Property and Joint Intellectual Property, to make, use, sell, offer to sell and import Royalty-Bearing Products incorporating Licensor Delivered Compounds; and
– a non-exclusive right and license in the Territory, with the right to grant sublicenses, under Licensors rights in the Licensors Intellectual Property other than the Licensor Composition Patent Rights, to make, use, sell, offer to sell and import Royalty-Bearing Products incorporating Limited License Compounds.
Product shall mean a medical device or a specialty catheter product developed for use in the Field, in either case incorporating one or more Licensor Nitric Oxide Releasing Compounds. Nitric Oxide Releasing Compounds shall mean compounds that donate, release and/or directly or indirectly transfer nitrogen monoxide, such that the biological activity of the nitrogen monoxide is expressed at an intended site of action.
Product relates to stents coated with nitric oxide-releasing compounds.
This development and license agreement is for the research, development and commercialization of cardiovascular stents coated with nitric oxide-enhancing medicines. Stents, or wire mesh devices, are typically inserted into narrowed coronary arteries to maintain blood flow.
IPSCIO Record ID: 5512
Abstact A vascular structure includes suitable mechanical properties needed to open and maintain a vessel, duct, tract, or organ and precise chronicity controlling the release and delivery of a bioactive agent carried on the vascular structure. The bioactive agent is capable of acting upon and altering the mechanisms of biologic systems in a manner providing a medicinal therapy. The vascular structure includes at least one layer or coating of the bioactive agent overlaid by a permiable membrane for controlling the osmotic release of the bioactive agent.
Technology also includes Patent Application Serial No. 08/797,743; Filed on February 7, 1997; 'Composition and Method For Making a Biodegradable Drug Delivery Stent'. Licensee is from Canada and licensor from U.S.
Abstract A stent or vascular graft for supporting a blood vessel or organ lumen is coated with a biodegradable, resorbable and hemocompatible surface substrate. Biologically active microspheres which controllably release the biologically active agent into the vessel wall or organ to inhibit restenosis of the stent is embedded in the stent substrate. The biologically active microspheres include encapsulated PGE1 in a water soluble polyethylene glycol mix, which over a period of time dissolves and releases the PGE1 into the vessel wall or organ.
USE OF TRADEMARKS. The Licensee will be allowed to use any and all trademarks of the Licensor with respect to the Technology, Products and any Improvements.
IPSCIO Record ID: 209508
At Licensees option, a non-exclusive, worldwide license to import, export, use, sell, and offer for sale Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.
The Covered Products means either or both Coated Stents and Licensee Stent Systems incorporating or utilizing Licensors Lubricious Coating.
The patents relate to Endovascular Stents and coatings.
Biolimus A9 is formulated to inhibit excessive tissue formation around the stent following implantation, a common side effect called restenosis which often threatens to reverse the clinical benefits of the angioplasty and stent implantation procedures.
In Japan, Licensees Licensed Field of Use is further limited to treating long lesions, multiple vessels or small vessels in coronary and peripheral applications.